Targeting the disturbed redox equilibrium in chronic lymphocytic leukemia by novel reactive oxygen species-catalytic...

Area of Science:

• Oncology
• Biochemistry
• Medicinal Chemistry

Background:

• Deregulated reactive oxygen species (ROS) are implicated in cancer progression, including precursor transformation, clonal expansion, and therapeutic resistance.
• Elevated ROS levels in chronic lymphocytic leukemia (CLL) present a potential therapeutic vulnerability.

Purpose of the Study:

• To develop novel therapeutic agents targeting CLL by exploiting its inherent redox burden.
• To design organochalcogen compounds that selectively induce cytotoxicity in CLL cells via ROS generation.

Main Methods:

• Design and synthesis of organochalcogen compounds based on a 'sensor/effector' principle.
• Evaluation of selective cytotoxicity in CLL cells versus normal cells.
• Assessment of apoptosis induction, normal cell toxicity, and chemotherapy synergism.

Main Results:

• The novel organochalcogen compounds demonstrated selective cytotoxicity, preferentially targeting CLL cells.
• Compounds efficiently induced apoptosis in cancer cells.
• Low toxicity was observed in normal cells, and promising synergism with chemotherapy was noted.

Conclusions:

• Organochalcogen-induced ROS generation is a viable therapeutic strategy for chronic lymphocytic leukemia.
• These findings support further investigation into the mechanistic and preclinical efficacy of this approach in CLL treatment.